WaveWriter Alpha Spinal Cord Stimulator (SCS) Mixed Systems, M8 Adaptor
Boston Scientific Corp · Decision date Dec 18, 2025
What did the FDA approve?
FDA records P030017/S374 as a supplement to PMA P030017, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Dec 18, 2025.
FDA approval order statement
Approval for 1) labeling updates to the WaveWriter Alpha Spinal Cord Stimulator (SCS) MRI Safety Guidelines to allow for Bl+rms limits to be set as the primary limiting condition for RF power, 2) a labeling update to the MRI Safety Guidelines and Precision Adapter M8 Instructions for Use to add the Medtronic Specify SureScan MRI Leads to the list of leads compatible with the BSN M8 Adapter as part of the WaveWriter Alpha Spinal Cord Stimulator (SCS) Mixed Systems, and 3) the WaveWriter Alpha SCS Mixed System using the Medtronic Specify SureScan leads will be labeled as MRI scan eligible.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Dec 18, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P030017/S374
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- LGW
- Decision code
- APPR
- Decision date
- Dec 18, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.
- Applicant
- Boston Scientific Corp
- Product code
- LGW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P030017. Subsequent supplements may change the device or its indications.
FDA decision timeline
P030017 · Original PMA
PRECISION SPINAL CORD STIMULATION(SCS) SYSTEM
P030017/S374 received
Application receipt date recorded by FDA.
P030017/S386 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S389 · Related supplement
WaveWriter Alpha Prime Spinal Cord Stimulation (SCS) Systems
P030017/S390 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S374 · FDA decision
Real-Time Process
P030017/S377 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S391 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S387 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems Introducer Hub Mold Change
P030017/S394 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S395 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S392 · Related supplement
Celestia Implantable Pulse Generator, Celestia External Trial Stimulator
P030017/S393 · Related supplement
Spinal Cord Stimulation (SCS)
P030017/S397 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S398 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S396 · Related supplement
WaveWriter Alpha and WaveWriter Alpha Prime SCS Systems; Celestia and Celestia Prime SCS Systems
P030017/S399 · Related supplement
Precision Spectra SCS Systems; Precision Novi SCS Systems; Precision Montage MRI SCS Systems; Spectra Wave Writer SCS Sy
Timeline entries are records held by MedtechLedger for P030017. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030017
Explore the linked device profile
Other records with product code LGW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 25155 Rye Canyon Loop, Valencia, CA, 91355
Sources and methodology
- Original FDA record: P030017/S374
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






